Structure Therapeutics News

Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Futu NewsSep 23 20:33

Structure Therapeutics Price Target Announced at $118.00/Share by Morgan Stanley

Dow JonesSep 23 20:18

Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksSep 23 19:59

Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118

Futu NewsSep 23 17:33

Structure Therapeutics Analyst Ratings

BenzingaSep 16 23:50

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

BenzingaSep 16 23:50

JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86

Futu NewsSep 11 01:32

Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning

TipRanksSep 11 00:38

Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Futu NewsSep 10 20:31

Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93

Futu NewsSep 10 19:33

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler

TipRanksSep 10 18:41

Structure Therapeutics Analyst Ratings

BenzingaAug 20 00:20

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

BenzingaAug 20 00:20

Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Futu NewsAug 15 20:31

Structure Therapeutics Analyst Ratings

BenzingaAug 15 20:22

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

BenzingaAug 15 20:22

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)

TipRanksAug 15 20:03

Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio

TipRanksAug 13 21:59

Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.

Zhitong FinanceAug 13 14:56

Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com

Barron'sAug 13 04:09